Abstract: A controllable optical device comprises a first substrate, a first conductive layer, a liquid crystal layer, a semiconductor conductive layer, a second conductive layer, and a second substrate. The first conductive layer is formed on the first substrate, the liquid crystal layer is formed on the first conductive layer, the semiconductor conductive layer is formed on the liquid crystal layer, the second conductive layer is formed on the semiconductor layer, and the second substrate is formed on the second conductive layer.

Abstract: A docetaxel inclusion complex having improved water-solubility (up to 15 mg/ml) and stability (stability constant Ka=2056 M?1-13051 M?1), comprises docetaxel and hydroxypropyl-beta-cyclodextrin and/or sulfobutyl-beta-cyclodextrin in a ratio of 1:10-150. The method includes steps as follows: docetaxel dissolved in ethanol is added into water solution of cyclodextrin via stirring, until docetaxel is completely dissolved; said solution is filtered in 0.2-04 ?m microporous membrane then ethanol is removed through reduced pressure to obtain the inclusion complex in a liquid form; or ethanol, followed by water is removed through reduced pressure, then dried to obtain the inclusion complex in a solid form.

Abstract: An electronic device includes a main body, a grip, and a slidable connecting device for connecting the grip to the main body. The slidable connecting device includes a flat block connected to the grip, a resilient loop arranged around a periphery of the flat block, and a sliding member comprising a first end securely coupled to the main body and a second end slidably connected to the flat block. The sliding member further includes a tab that is arranged between the periphery and the resilient loop and is used to tension the resilient loop, enabling the resilient loop to be able to apply a force to the tab, thereby allowing the sliding member to be positioned at a desired position by the force.

Abstract: A docetaxel inclusion complex having improved water-solubility (up to 15 mg/ml) and stability (stability constant Ka=2056 M?1-13051 M?1), comprises docetaxel and hydroxypropyl-beta-cyclodextrin and/or sulfobutyl-beta-cyclodextrin in a ratio of 1:10-150. The method includes steps as follows: docetaxel dissolved in ethanol is added into water solution of cyclodextrin via stirring, until docetaxel is completely dissolved; said solution is filtered in 0.2-04 ?m microporous membrane then ethanol is removed through reduced pressure to obtain the inclusion complex in a liquid form; or ethanol, followed by water is removed through reduced pressure, then dried to obtain the inclusion complex in a solid form.

Abstract: In a flame identification method and device for identifying any flame image in a plurality of frames captured consecutively from a monitored area, for each image frame, intensity foreground pixels are obtained based on intensity values of pixels, a fire-like image region containing the intensity foreground pixels is defined when an intensity foreground area corresponding to the intensity foreground pixels is greater than a predetermined intensity foreground area threshold, and saturation foreground pixels are obtained from all pixels in the fire-like image region based on saturation values thereof to obtain a saturation foreground area corresponding to the saturation foreground pixels. Linear regression analyses are performed on two-dimensional coordinates each formed by the intensity and saturation pixel areas associated with a corresponding image frame to generate a determination coefficient.

Abstract: A docetaxel inclusion complex having improved water-solubility (up to 15 mg/ml) and stability (stability constant Ka=2056M?1-13051M?1), comprises docetaxel and hydroxypropyl-beta-cyclodextrin and/or sulfobutyl-beta-cyclodextrin in a ratio of 1:10-150. The method includes steps as follows: docetaxel dissolved in ethanol is added into water solution of cyclodextrin via stirring, until docetaxel is completely dissolved; said solution is filtered in 0.2-04 ?m microporous membrane then ethanol is removed through reduced pressure to obtain the inclusion complex in a liquid form; or ethanol, followed by water is removed through reduced pressure, then dried to obtain the inclusion complex in a solid form.

Abstract: A pharmaceutical composition comprising cyclodextrin/paclitaxel inclusion, which consists of paclitaxel, cyclodextrin and a pharmaceutically acceptable excipient, wherein the mass ratio of the paclitaxel to cyclodextrin is 1:10-150, the said cyclodextrin is hydroxylpropyl-sulfobutyl-7-?-cyclodextrin, or sulfobutylether-7-?-cyclodextrin, or their mixture; the stability constant of the cyclodextrin/paclitaxel inclusion is Ka=5396M?1?1412M?1. The preparation method of the pharmaceutical composition is as follow: (a) A solution of cyclodextrin is added dropwise to a solution of paclitaxel in ethanol. (b) The resulting mixture is filtered through microporous membrane of 0.2-0.4 ?m after being dissolved. (c) Ethanol is removed under reduced pressure to give a liquid inclusion which has the ethanol level of less than 2%, or alternatively water is also removed under reduced pressure, the resulting product is dried giving a solid inclusion.

Abstract: A controllable optical device comprises a first substrate, a first conductive layer, a liquid crystal layer, a semiconductor conductive layer, a second conductive layer, and a second substrate. The first conductive layer is formed on the first substrate, the liquid crystal layer is formed on the first conductive layer, the semiconductor conductive layer is formed on the liquid crystal layer, the second conductive layer is formed on the semiconductor layer, and the second substrate is formed on the second conductive layer.

Abstract: Hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin, the preparation method, analytical method, and the pharmaceutical application thereof. The hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin is a derivate of cyclodextrin which is substituted by hydroxypropyl group and sulfobutyl group: n-(2,3,6-O-2-hydroxypropyl)-m-(2,3,6-O-sulfobutyl)-&bgr;-cyclodextrin. The number of substituent groups per mole cyclodextrin is n hydroxypropyl groups and m sulfobutyl groups. “n” represents the average substituent degree of hydroxypropyl groups; “m” represents the average substituent degree of sulfobutyl groups; “n+m=z” is the gross average substituent degree, in which n is a random integer chosen from 1,2,3,4,5,6,7,8,9; m is a random integer chosen from 1,2,3,4,5,6,7,8,9; and the gross average substituent degree z is a random integer chosen from 2,3,4,5,6,7,8,9,10. The present invention shows low haemolysis and low toxicity.

Abstract: This disclosure describes a user interface (UI) conceptual model and a data model for quickly and easily developing and managing a GUI. The present methods and systems described herein provide for defining one or more UI elements in the UI conceptual model. The one or more UI elements may further reference one or more model objects in the data model. The one or more model objects may include one or more tasks, which may each be mapped to one or more commands for performing each task, or one or more data items, which may each be mapped to rules or conditions for transforming data. According to embodiments, graphics or functionality of a GUI may be easily and efficiently modified by adding, deleting, or modifying UI elements in the UI conceptual model or by adding, deleting, or modifying referenced model objects in the data model, thereby reducing management and development costs.

Abstract: In a flame identification method and device for identifying any flame image in a plurality of frames captured consecutively from a monitored area, for each image frame, intensity foreground pixels are obtained based on intensity values of pixels, a fire-like image region containing the intensity foreground pixels is defined when an intensity foreground area corresponding to the intensity foreground pixels is greater than a predetermined intensity foreground area threshold, and saturation foreground pixels are obtained from all pixels in the fire-like image region based on saturation values thereof to obtain a saturation foreground area corresponding to the saturation foreground pixels. Linear regression analyses are performed on two-dimensional coordinates each formed by the intensity and saturation pixel areas associated with a corresponding image frame to generate a determination coefficient.

Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor PTHR1, also known as parathyroid hormone/parathyroid hormone related protein receptor. The PTHR1 compounds are derived from the intracellular loops and domains of the PTHR1 receptor. The invention also relates to the use of these PTHR1 receptor compounds and pharmaceutical compositions comprising the PTHR1 receptor compounds in the treatment of diseases and conditions associated with PTHR1 receptor modulation, such as osteoporosis; humoral hypercalcemia of malignancy; osteolytic and osteoblastic metastasis to bone; primary and secondary hyperparathyroidism associated increase in bone absorption; vascular calcification; psychiatric disorders and cognitive disorders associated with hyperparathyroidism; dermatological disorders; and excess hair growth.

Abstract: A nickel-hydrogen battery pack heat removal system for hybrid vehicle is provided. The system includes a battery box, a power battery pack (8), a battery support frame (9), a support bar (5), an air inlet (1), an air outlet (6) and a fan (7). Batteries in the power battery pack (8) are aligned in parallel in two layers one above the other in the battery support frame (9) of the battery box, and the support bar (5) and the battery support frame (9) are fixed on the upper and lower soleplates respectively of the battery box. The air inlet (1) is set at one end of the battery box, the air outlet (6) is set at the other end of the battery box, and the fan (7) is fitted at the air outlet (6). The system further includes conduction plates (2) in the shape of circular arcs, said conduction plates (2) being fitted on the opposing faces of the two upper and lower batteries which are closest to the air inlet (1).

Abstract: A docetaxel inclusion complex having improved water-solubility (up to 15 mg/ml) and stability (stability constant Ka=2056M?1-13051M?1), comprises docetaxel and hydroxypropyl-beta-cyclodextrin and/or sulfobutyl-beta-cyclodextrin in a ratio of 1:10-150. The method includes steps as follows: docetaxel dissolved in ethanol is added into water solution of cyclodextrin via stirring, until docetaxel is completely dissolved; said solution is filtered in 0.2-04 ?m microporous membrane then ethanol is removed through reduced pressure to obtain the inclusion complex in a liquid form; or ethanol, followed by water is removed through reduced pressure, then dried to obtain the inclusion complex in a solid form.

Abstract: A pharmaceutical composition comprising cyclodextrin/paclitaxel inclusion, which consists of paclitaxel, cyclodextrin and a pharmaceutically acceptable excipient, wherein the mass ratio of the paclitaxel to cyclodextrin is 1:10-150, the said cyclodextrin is hydroxylpropyl-sulfobutyl-7-?-cyclodextrin, or sulfobutylether-7-?-cyclodextrin, or their mixture; the stability constant of the cyclodextrin/paclitaxel inclusion is Ka=5396M?1?1412M?1. The preparation method of the pharmaceutical composition is as follow: (a) A solution of cyclodextrin is added dropwise to a solution of paclitaxel in ethanol. (b) The resulting mixture is filtered through microporous membrane of 0.2-0.4 ?m after being dissolved. (c) Ethanol is removed under reduced pressure to give a liquid inclusion which has the ethanol level of less than 2%, or alternatively water is also removed under reduced pressure, the resulting product is dried giving a solid inclusion.

Abstract: Apparatus for user removable memory, the memory for providing functional expansion to an associated electronic device, the apparatus comprising an interface configured for converting signalling between file access signalling for an associated electronic device and appropriate signalling for the use by the memory in providing the functional expansion.

Abstract: Hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin, the preparation method, analytical method, and the pharmaceutical application thereof. The hydroxypropyl-sulfobutyl-&bgr;-cyclodextrin is a derivate of cyclodextrin which is substituted by hydroxypropyl group and sulfobutyl group: n-(2,3,6-O-2-hydroxypropyl)-m-(2,3,6-O-sulfobutyl)-&bgr;-cyclodextrin. The number of substituent groups per mole cyclodextrin is n hydroxypropyl groups and m sulfobutyl groups. “n” represents the average substituent degree of hydroxypropyl groups; “m” represents the average substituent degree of sulfobutyl groups; “n+m=z” is the gross average substituent degree, in which n is a random integer chosen from 1, 2, 3, 4, 5, 6, 7, 8, 9; m is a random integer chosen from 1, 2, 3, 4, 5, 6, 7, 8, 9; and the gross average substituent degree z is a random integer chosen from 2, 3, 4, 5, 6, 7, 8, 9, 10. The present invention shows low haemolysis and low toxicity.

Abstract: An electrohydraulic shock wave-generating system for extracorporeal therapy of renal stones or musculoskeletal disorders includes a shock wave generator, a micro high-sensitivity camera, and a gap-controlling unit. The shock wave generator includes a truncated ellipsoidal bowl and two electrodes, each electrode having a portion inside the bowl, with a gap being defined between the electrodes. The micro high-sensitivity camera acquires an image of the electrodes for finding a size of the gap. The gap-controlling unit controls the size of the gap and moves at least one of the electrodes to adjust the size of the gap. A medical treatment for fragmenting stones or for curing musculoskeletal disorders can be carried out without increasing the operational voltage applied to the electrodes under gap control provided by the system. The system also includes a computer control unit to provide automatic control of the gap.

Abstract: A tracking system for stone treatment by extracorporeal shock wave lithotripsy includes a data processing unit, a motion controller, a servo-moving platform, a stone image-processing module, a stone localization module, and a moving-mechanism control module. With the use of the stone-tracking system, the performance of an extracorporeal shock wave lithotriptor can be greatly improved, resulting in less side effect such as tissue damage.

Abstract: A tracking system for stone treatment by extracorporeal shock wave lithotripsy includes a data processing unit, a motion controller, a servo-moving platform, a stone image-processing module, a stone localization module, and a moving-mechanism control module. With the use of the stone-tracking system, the performance of an extracorporeal shock wave lithotriptor can be greatly improved, resulting in less side effect such as tissue damage.